血栓性微血管病 中国就医指南

Thrombotic Microangiopathy (TMA) is a life-threatening hematologic syndrome characterized by systemic microvascular thrombosis, mechanical hemolytic anemia, thrombocytopenia, and end-organ damage—most commonly affecting the kidneys and central nervous system. It is not a single disease but a pathological phenotype shared by several distinct disorders, including thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), complement-mediated TMA (e.g., atypical HUS), drug-induced TMA, malignancy-associated TMA, and secondary forms linked to autoimmune diseases (e.g., SLE), infections (e.g., Shiga-toxin–producing E. coli, HIV), pregnancy (eclampsia/HELLP), or transplantation. Pathogenesis centers on endothelial injury and dysregulation of the von Willebrand factor (VWF)–ADAMTS13 axis or the alternative complement pathway. In acquired TTP, autoantibodies inhibit ADAMTS13 protease activity, causing accumulation of ultra-large VWF multimers that promote platelet-rich microthrombi. In atypical HUS, gain-of-function mutations or autoantibodies in complement regulatory proteins (e.g., CFH, CFI, MCP) lead to uncontrolled complement activation on endothelial surfaces. Epidemiologically, TMA is rare: idiopathic TTP incidence is ~3–6 cases per 10 million annually; pediatric typical HUS occurs at ~2–3 per 100,000 children per year, often post-diarrheal. Atypical HUS accounts for ~5–10% of all HUS cases and may present at any age, with higher prevalence in adults. Risk factors include genetic predisposition (e.g., CFH mutations), female sex (especially in pregnancy-related TMA), advanced age, underlying autoimmune or malignant conditions, certain medications (e.g., calcineurin inhibitors, chemotherapy agents like gemcitabine or mitomycin C), and infections. Early diagnosis is critical—delayed treatment carries mortality rates exceeding 90% in untreated TTP. Quality of life impact is profound: survivors frequently experience chronic kidney disease requiring dialysis or transplant, cognitive deficits, fatigue, hypertension, depression, and anxiety. Many patients face long-term disability, reduced work capacity, and recurrent hospitalizations. Psychosocial burden extends to caregivers, with financial strain from repeated plasma exchange, immunosuppression, and monitoring. Children may suffer developmental delays or growth impairment. Even with modern therapies—including therapeutic plasma exchange (TPE), caplacizumab, eculizumab, ravulizumab, and corticosteroids—relapse risk remains significant, necessitating lifelong surveillance. Multidisciplinary care involving hematologists, nephrologists, neurologists, and transplant specialists is essential for optimal outcomes.

# 血栓性微血管病（TMA）治疗方案与费用明细（血液科）

一、非手术/药物/支持治疗方案

适用人群：初发、轻中度ADAMTS13缺乏型TTP、补体介导aHUS稳定期、药物/感染相关TMA缓解期患者。

• •一线药物治疗（含血浆置换+免疫抑制）：

- 利妥昔单抗（375 mg/m²×4周）：2.4万–3.6万元/疗程（国产 vs 进口）； - 糖皮质激素（甲泼尼龙冲击+口服）：800–1500元/疗程；

• •检查检验费（首周必需）：ADAMTS13活性+抗体、补体CH50/C3/C5b-9、外周血涂片、LDH、肾功、凝血谱等：2600–3800元。

二、核心介入/靶向治疗方案

适用人群：难治/复发TTP、补体依赖型aHUS、eculizumab耐药者。

• •补体抑制剂治疗（依库珠单抗）：

• •术前检查费（含基因检测、流式细胞术、骨髓活检）：4100–6300元。

三、特殊复杂/晚期方案

• •造血干细胞移植（仅限遗传性CFH/CFI突变、反复复发aHUS）：全流程（预处理+回输+隔离护理）：38万–52万元；
• •联合免疫清除+新型C5抑制剂（ravulizumab）：年治疗费45万–60万元。

方案快速选择指南

• •预算≤5万元：首选PEX+糖皮质激素+利妥昔单抗（国产）；
• •预算15–30万元：依库珠单抗标准方案（医保谈判后自付约30%）；
• •复发/遗传性/儿童患者：建议基因检测+补体靶向+移植评估。